Quell® Wearable Neuromodulator to be Evaluated in
Post# of 8565
(Total Views: 408)
Posted On: 03/18/2022 2:57:41 PM
Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome
2 years ago when someone on another board suggested ActiPatch be evaluated for use against Covid, it got a chuckle out of me. ActiPatch does amazing things for the body in relation to Pain Relief, Inflammation, Healing Damaged Cells, but I did not see how it could defeat an aggressive Virus.
Now we have Quell, which is a fancy TENS device, being evaluated by the National Science Foundation for use to reduce the 'Long Covid' symptoms that are affecting 10 million in the US.
PSWT/PEMF has proven to be superior to TENS in numerous aspects. There is no reason that PSWT would not be better suited for treating many of the Long Covid symptoms than TENS.
ActiPatch has a big following in the Fibromyalgia community and many Long Covid symptoms are the same issues that Fibromyalgia patients experience.
WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome PACS, or "long COVID". The trial will be conducted at the Baylor College of Medicine in collaboration with the National Science Foundation (NSF) funded Center to Stream Healthcare In Place (C2SHIP). The principal investigator is Dr. Bijan Najafi, Professor of Surgery, and clinical director at the Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine.
Over 10 million Americans are estimated to be living with PACS. This condition is defined as persistent symptoms following an acute COVID-19 infection. It may affect over one-third of individuals who had COVID-19, even those whose initial disease was mild or asymptomatic. PACS is characterized by a constellation of symptoms that include fatigue, joint pain, muscle pain, memory and concentration issues, sleep problems, shortness of breath, cough, and heart rate abnormalities. Many of these symptoms are also characteristic of fibromyalgia. In a recently published study, 31% of individuals who experienced an acute COVID-19 infection met the American College of Rheumatology (ACR) criteria for fibromyalgia when surveyed an average of 6-months following infection. PACS treatment is challenging and there is an unmet need for effective therapies.
https://www.globenewswire.com/news-release/20...drome.html
2 years ago when someone on another board suggested ActiPatch be evaluated for use against Covid, it got a chuckle out of me. ActiPatch does amazing things for the body in relation to Pain Relief, Inflammation, Healing Damaged Cells, but I did not see how it could defeat an aggressive Virus.
Now we have Quell, which is a fancy TENS device, being evaluated by the National Science Foundation for use to reduce the 'Long Covid' symptoms that are affecting 10 million in the US.
PSWT/PEMF has proven to be superior to TENS in numerous aspects. There is no reason that PSWT would not be better suited for treating many of the Long Covid symptoms than TENS.
ActiPatch has a big following in the Fibromyalgia community and many Long Covid symptoms are the same issues that Fibromyalgia patients experience.
WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome PACS, or "long COVID". The trial will be conducted at the Baylor College of Medicine in collaboration with the National Science Foundation (NSF) funded Center to Stream Healthcare In Place (C2SHIP). The principal investigator is Dr. Bijan Najafi, Professor of Surgery, and clinical director at the Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine.
Over 10 million Americans are estimated to be living with PACS. This condition is defined as persistent symptoms following an acute COVID-19 infection. It may affect over one-third of individuals who had COVID-19, even those whose initial disease was mild or asymptomatic. PACS is characterized by a constellation of symptoms that include fatigue, joint pain, muscle pain, memory and concentration issues, sleep problems, shortness of breath, cough, and heart rate abnormalities. Many of these symptoms are also characteristic of fibromyalgia. In a recently published study, 31% of individuals who experienced an acute COVID-19 infection met the American College of Rheumatology (ACR) criteria for fibromyalgia when surveyed an average of 6-months following infection. PACS treatment is challenging and there is an unmet need for effective therapies.
https://www.globenewswire.com/news-release/20...drome.html
(1)
(0)